{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:53:25Z","timestamp":1791665605307,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009448","name":"University of Campania Luigi Vanvitelli","doi-asserted-by":"publisher","award":["2019\/LS14-442"],"award-info":[{"award-number":["2019\/LS14-442"]}],"id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.numecd.2025.104284","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T15:14:07Z","timestamp":1755962047000},"page":"104284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-7533","authenticated-orcid":false,"given":"Alfredo","family":"Caturano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Galiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Simeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Acierno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Nilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Consiglia","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Vetrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestino","family":"Sardu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"D'Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Chiodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Marfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Balestrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando Carlo","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.numecd.2025.104284_bib1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s12072-024-10702-5","article-title":"A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"issue":"8","key":"10.1016\/j.numecd.2025.104284_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.numecd.2025.104284_bib3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.31083\/j.rcm2203082","article-title":"Pathophysiological mechanisms and clinical evidence of relationship between nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease","volume":"22","author":"Galiero","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.numecd.2025.104284_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.37349\/emed.2020.00019","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin","volume":"1","author":"Acierno","year":"2020","journal-title":"Explor Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104284_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14737159.2018.1415145","article-title":"MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury","volume":"18","author":"Howell","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.numecd.2025.104284_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112116","article-title":"A comprehensive review of miR-21 in liver disease: big impact of little things","volume":"134","author":"Xue","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.numecd.2025.104284_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/ph14020122","article-title":"The current and potential therapeutic use of metformin-the good old drug","volume":"14","author":"Drzewoski","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.numecd.2025.104284_bib8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.5009\/gnl20367","article-title":"Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels","volume":"15","author":"Pinyopornpanish","year":"2021","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.numecd.2025.104284_bib9","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk","volume":"15","author":"Jasleen","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.numecd.2025.104284_bib10","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.5114\/amsad.2021.105314","article-title":"Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state","volume":"6","author":"Papaetis","year":"2021","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"10","key":"10.1016\/j.numecd.2025.104284_bib11","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.numecd.2025.104284_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.numecd.2025.104284_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111513","article-title":"In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia","volume":"22","author":"H\u00fcttl","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.numecd.2025.104284_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/biomedicines11020322","article-title":"Effects of a combination of empagliflozin plus metformin vs. metformin monotherapy on NAFLD progression in type 2 diabetes: the IMAGIN pilot study","volume":"11","author":"Caturano","year":"2023","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.numecd.2025.104284_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (chronic kidney disease epidemiology collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104284_bib16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.numecd.2025.104284_bib17","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/diagnostics12102287","article-title":"Ultrasound methods for the assessment of liver steatosis: a critical appraisal","volume":"12","author":"Bozic","year":"2022","journal-title":"Diagnostics"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2025.104284_bib18","first-page":"S111","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104284_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.739875","article-title":"Validation of controlled attenuation parameter measured by FibroScan as a novel surrogate marker for the evaluation of metabolic derangement","volume":"12","author":"Huang","year":"2022","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.numecd.2025.104284_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1479164115616901","article-title":"Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus","volume":"13","author":"Neeland","year":"2016","journal-title":"Diabetes Vasc Dis Res"},{"issue":"1","key":"10.1016\/j.numecd.2025.104284_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.numecd.2025.104284_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000783","article-title":"Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet","volume":"7","author":"Xu","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.numecd.2025.104284_bib23","first-page":"121","article-title":"Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization","volume":"7","author":"Xu","year":"2018","journal-title":"Adipocyte"},{"issue":"1","key":"10.1016\/j.numecd.2025.104284_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12020-024-03702-w","article-title":"Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome","volume":"85","author":"Mladenovi\u0107","year":"2024","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.numecd.2025.104284_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jcpt.13521","article-title":"Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: a network meta-analysis based on randomized controlled trials","volume":"47","author":"Wu","year":"2022","journal-title":"J Clin Pharm Therapeut"},{"issue":"12","key":"10.1016\/j.numecd.2025.104284_bib26","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.3390\/biomedicines10123294","article-title":"New insights into the use of Empagliflozin-A comprehensive review","volume":"10","author":"Forycka","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.numecd.2025.104284_bib27","doi-asserted-by":"crossref","first-page":"goae029","DOI":"10.1093\/gastro\/goae029","article-title":"Advancements in pharmacological treatment of NAFLD\/MASLD: a focus on metabolic and liver-targeted interventions","volume":"12","author":"Ciardullo","year":"2024","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"3","key":"10.1016\/j.numecd.2025.104284_bib28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"issue":"8","key":"10.1016\/j.numecd.2025.104284_bib29","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.numecd.2025.104284_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.numecd.2025.104284_bib31","article-title":"The effect of empagliflozin on liver fat in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease","volume":"13","author":"Pokharel","year":"2021","journal-title":"Cureus"},{"issue":"3.4","key":"10.1016\/j.numecd.2025.104284_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2152\/jmi.67.280","article-title":"Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus","volume":"67","author":"Shinozaki","year":"2020","journal-title":"J Med Investig"},{"issue":"8","key":"10.1016\/j.numecd.2025.104284_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J Diabet Complicat"},{"issue":"4","key":"10.1016\/j.numecd.2025.104284_bib34","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.numecd.2025.104284_bib35","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.numecd.2025.104284_bib36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jfma.2021.07.013","article-title":"The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: a diagnostic or screening tool?","volume":"121","author":"Xu","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"10.1016\/j.numecd.2025.104284_bib37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.numecd.2025.104284_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cld.1183","article-title":"Nonalcoholic fatty liver disease: the role of visceral adipose tissue","volume":"19","author":"Hanlon","year":"2022","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.numecd.2025.104284_bib39","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1038\/s41598-023-30527-w","article-title":"Different correlation of body mass index with body fatness and obesity-related biomarker according to age, sex and race-ethnicity","volume":"13","author":"Jeong","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.numecd.2025.104284_bib40","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/oby.23425","article-title":"Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes","volume":"30","author":"Waddell","year":"2022","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.numecd.2025.104284_bib41","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.2337\/dc13-0102","article-title":"Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss","volume":"36","author":"Haufe","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.numecd.2025.104284_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.mayocp.2018.09.019","article-title":"Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials","volume":"94","author":"Rao","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.numecd.2025.104284_bib43","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/liv.12429","article-title":"Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease","volume":"34","author":"Miyaaki","year":"2014","journal-title":"Liver Int"},{"issue":"21","key":"10.1016\/j.numecd.2025.104284_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111513","article-title":"In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia","volume":"22","author":"H\u00fcttl","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.numecd.2025.104284_bib45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol Med"},{"key":"10.1016\/j.numecd.2025.104284_bib46","article-title":"Critical role of microRNA-21 in the pathogenesis of liver diseases","volume":"7:7","author":"Zhang","year":"2020","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104284_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46288-5","article-title":"Empagliflozin suppresses hedgehog pathway, alleviates ER stress, and ameliorates hepatic fibrosis in rats","volume":"13","author":"Abdalla","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.numecd.2025.104284_bib48","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2214\/AJR.07.4016","article-title":"Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis","volume":"192","author":"Webb","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.numecd.2025.104284_bib49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2017.04.003","article-title":"Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic\/histological parameters in various liver diseases","volume":"72","author":"Ballestri","year":"2017","journal-title":"Metabolism"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325004387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325004387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:55:08Z","timestamp":1772873708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325004387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0939475325004387"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104284","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104284"}}